Wednesday, September 14th, 2022

08:30 // Registration and coffee

09:00 // Welcome

09:15 // SESSION 1: Will molecular tests enable sustainable precision medicine? 

               Chair: Kristin Austlid Taskén, Oslo University Hospital (NO)

09:15 // Genomics/PARP-I in Prostate Cancer: What, when and who

              Maha Hussain, Northwestern University Feinberg School of Medicine (US)

09:45 // Will biomarkers - other than PSA - be used to guide treatment of advanced prostate cancer?

              Nicolas Mottet,  University Hospital St. Etienne and University Jean Monnet  (FR)

10:15 // How cost-effective are biomarkers?

             Derya Tilki, Martini-Klinik Prostate Cancer Centre, Hamburg (DE)

10:45 // Short talk - selected from abstract

11:00 // Break

11:30 // SESSION 2: Providing evidence for implementing molecular tests in clinical guidelines

              Chair: Rolf Skotheim, Oslo University Hospital (NO)

11:30 // Requirements for implementation of molecular tests into guidelines

              Himisha Beltran, Dana-Farber Cancer Institute and Harvard Medical School (US)

              Dentist Olaf Aase and wife memorial lecture

12:00 // Extracellular vesicles - from lab to clinical implementation

             Johan Skog, Exosome Diagnostics (US)

12:30 // Short talk - selected from abstract


12:40 // Short talk - selected from abstract 

13:00 // Lunch

14:00 // Biomarker-driven precision medicine in Norway - where we are and where to go

             Hege Russnes, Oslo University Hospital (NO)

14:15 // How to bring molecular tests into the clinic in Scandinavia

            Henrik Grönberg, Karolinska Institutet and Capio S:t Göran Hospital (SE)

14:45 // Break

15:00 // Panel Discussion (in Norwegian)

              - How and when can molecular tests provide sustainable precision medicine in the clinic?

              Moderator Elisabeth Kirkeng Andersen (NO)

16:00 // Poster session

17:00 // Social activities (Munch museum, sauna, walk)

19:00 // Dinner (including Poster Awards)

Thursday, September 15th, 2022

09:00 // SESSION 3: Precision medicine: impact of the tumour microenvironment 

              Chair: Heidi Lyng, Oslo University Hospital (NO)

09:00 // Everything in balance? Metabolism reprograms cells

              Ian Mills, University of Oxford, Queen’s University of Belfast and University of Cambridge (UK) ​

09:30 // Hypoxia and subclonal evolution 

              Rob Bristow, Manchester Cancer Research Centre, CRUK Major research Centre, University of Manchester (UK)

10:00 // How can we move forward with immunotherapy in prostate cancer?  

              Johanna Olweus, Oslo University Hospital (NO)

10:15 // Break

10:45 // Discovery and testing of biomarkers and drugs in ex vivo and in vivo model systems

              Wytske van Weerden, Erasmus Medical Center (NL)

11:15 // Biomarker potential of tumor hypoxia

              Heidi Lyng, Oslo University Hospital (NO)

11:30 // Lunch 

12:30 // Reversing off-target prostate cancer resistance

              Mark Rubin, University of Bern (CH)

13:00 // Short talk - selected from abstract

13:10 // Short talk - selected from abstract

13:20 // SESSION 4: Pitfalls and opportunities in biomarker discovery

              Chair: Alicia Llorente, Oslo University Hospital (NO)

13:20 // Functional and spatial precision cancer medicine

             Olli Kallioniemi, Karolinska Institutet (SE)

13:50 // Break

14:20 // Exploring precision oncology: From gene fusions to lncRNAs

              Arul Chinnaiyan, Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)

14:50 // Multifocal prostate cancer and implications for precision oncology

             Rolf Skotheim, Oslo University Hospital (NO)

15:05 // Analysis of urinary extracellular vesicles form the discovery of prostate cancer biomarkers

             Alicia Llorente, Oslo University Hospital (NO)

15:20 // European network for biomarker validation

             Guido Jenster, Erasmus Medical Centre (NL)


16:00 // Closing remarks